VJHemOnc is committed to improving our service to you

BOPA 2017 | TOURMALINE-MM1 study produces optimistic results for MM

VJHemOnc is committed to improving our service to you

Alberto Rocci

The ongoing TOURMALINE-MM1 study (NCT01564537), a Phase III placebo-controlled clinical trial for relapsed refractory multiple myeloma, has produced very positive response results, even in patients with high-risk cytogenetics – a result, which, if validated, is unprecedented. Alberto Rocci, MD from Central Manchester University Hospital, Manchester, UK discusses these results and the toxicity profile of the novel oral triplet combination treatment used, which includes ixazomib. This interview was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK. This content has been supported by Napp Pharmaceuticals through an unrestricted educational grant to Magdalen Medical Publishing. The company has had no influence on the production of the content.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter